Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project
- 22 August 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 73 (11), 1499-1510
- https://doi.org/10.1007/s00228-017-2317-0
Abstract
After regulatory restrictions for terfenadine and astemizole in ‘90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of individual antihistamines. A matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project. Data on 1997–2010 were retrieved from seven healthcare databases: AARHUS (Denmark), GEPARD (Germany), HSD and ERD (Italy), PHARMO and IPCI (Netherlands) and THIN (UK). Cases of VA were selected and up to 100 controls were matched to each case. The odds ratio (OR) of current use for individual antihistamines (AHs) was estimated using conditional logistic regression. For agents largely used to prevent allergic symptoms, such as cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, we found no VA risk. A statistically significant, increased risk of VA was found only for current use of cyclizine in the pooled analysis (ORadj, 5.3; 3.6–7.6) and in THIN (ORadj, 5.3; 95% CI, 3.7–7.6), for dimetindene in GEPARD (ORadj, 3.9; 1.1–14.7) and for ebastine in GEPARD (ORadj, 3.3; 1.1–10.8) and PHARMO (ORadj, 4.6; 1.3–16.2). The risk of VA associated with a few specific antihistamines could be ascribable to heterogeneity in pattern of use or in receptor binding profile.Keywords
This publication has 23 references indexed in Scilit:
- Determining the Pathogenicity of Genetic Variants Associated with Cardiac ChannelopathiesScientific Reports, 2015
- The effects of antihistamines with varying anticholinergic properties on voluntary and involuntary movementClinical Neurophysiology, 2013
- Assessing cardiovascular drug safety for clinical decision-makingNature Reviews Cardiology, 2013
- Histamine and H1-antihistamines: Celebrating a century of progressJournal of Allergy and Clinical Immunology, 2011
- Heart Rhythm Disturbances Associated With Rupatadine: A Case Series From the Spanish and Portuguese Pharmacovigilance SystemsClinical Pharmacology & Therapeutics, 2009
- Hydroxyzine, a First Generation H1-Receptor Antagonist, Inhibits Human Ether-a-go-go–Related Gene (HERG) Current and Causes Syncope in a Patient With the HERG MutationJournal of Pharmacological Sciences, 2008
- Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjectsBritish Journal of Clinical Pharmacology, 2005
- The significance of QT interval in drug developmentBritish Journal of Clinical Pharmacology, 2002
- Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels.2000
- Molecular Basis for the Lack of HERG K+Channel Block-Related Cardiotoxicity by the H1Receptor Blocker Cetirizine Compared with Other Second-Generation AntihistaminesMolecular Pharmacology, 1998